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Abstract 
 
The regulation of proprotein convertase subtilisin/kexin type 9 
(PCSK9) and cholesterol homeostasis by microRNAs 
 
Chan Joo Lee 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Sahng Wook Park) 
 
 
Low density lipoprotein (LDL) receptor on the cellular membrane is a 
receptor responsible for uptake of serum LDL-cholesterol into the cell. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the LDL 
receptor (LDLR), followed by internalization of the complex and degradation 
of LDLR, and ultimately regulates cholesterol homeostasis. Transcription of 
PCSK9 is regulated by SREBP (sterol regulatory element binding protein) but 
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regulation by microRNA (miRNA) is still not known. The purpose of this 
study is to show the existence of miRNA regulating PCSK9 and involving 
cholesterol homeostasis. In order to discover the posttranscriptional regulation 
mechanism of PCSK9, bioinformatic algorithms were utilized to discover 
miRNAs expected to target PCSK9. Overexpression of these miRNAs 
reduced both PCSK9 mRNA and protein significantly whereas increased 
LDLR protein. 3ʹUTR (untranslated region) luciferase reporter assay showed 
that these miRNAs downregulated PCSK9 expression by binding 3ʹUTR of 
PCSK9. Site-directed mutagenesis of predicted seed region in PCSK9 mRNA 
revealed specific interaction between miRNAs and PCSK9 mRNA. In Dil-
LDL uptake assay, overexpression of these miRNA demonstrated a relative 
increase in Dil-LDL uptake by 70% or greater. In addition, it was indentified 
that miR-224 regulated the inducible degrader of the LDL receptor (IDOL) by 
3ʹUTR reporter assay. These indicate that miRNAs may be yet another 
mechanism involved in cholesterol homeostasis by posttranscriptional 
regulation of PCSK9 or IDOL and that utilization of miRNA may be a method 
of treatment of hypercholesterolemia. 
 
 
Key words: PCSK9, LDL receptor, microRNA, hypercholesterolemia 
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I. INTRODUCTION 
Proprotein convertase subtilisin/kexin 9 (PCSK9), a type of proteinases 
that undertake restrictive proteolysis, is known to promote the breakdown of 
low density lipoprotein receptor (LDLR), which uptakes cholesterol at the cell 
membrane and regulates the cholesterol level in the blood. Typically, LDLR is 
endocytosed when it binds to lipoproteins on the surface of the cell membrane, 
then recycled after the bound lipoprotein is dissociated under the low pH 
environment in the endosome.1,2 PCSK9 binds to the first epidermal growth 
3 
 
factor-like repeat A domain of LDLR, and the PCSK9-LDLR complex is 
endocytosed even without binding of lipoproteins to LDLR. LDLR on the 
PCSK9-LDLR complex is directed to the lysosome and degraded instead of 
being recycled.3 The gain of function mutation of PCSK9 results in a 
reduction of LDLR, leading to an increase in blood LDL cholesterol 
concentration.4 On the contrary, the loss of function of PCSK9 results in 
relatively less LDLR destruction, leading to increased absorptions of LDL 
cholesterol into the cell, and ultimately lowers the incidence of coronary 
artery disease of which the main risk factor is hypercholesterolemia.5 By 
altering the expression level of LDLR, the qualitative and quantitative change 
of PCSK9 affects cholesterol related diseases. 
Cellular cholesterol is regulated by a transcriptional factor called sterol 
regulatory element binding protein (SREBP), especially by SREBP-2.6 An 
increase in SREBP-2 transcription due to a decrease in cellular cholesterol 
level leads to an increased expression of LDLR, which manages the 
absorption of LDL cholesterol in the blood and the expression of 3-hydroxy-
3-methyglutaryl coenzyme A reductase (HMG-CoA reducatase), the most 
critical enzyme in synthesizing cholesterol.7,8 Moreover, SREBP-2 causes an 
increase not only in LDLR expression, but also in PCSK9 expression.9,10 
The primary mechanism by which statin-related substances, the medicine 
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for hypercholesterolemia, decrease the blood cholesterol level is to reduce 
endogenous cholesterol synthesis by blocking HMG-CoA reductase in liver 
cells. The compensatory mechanism that increases the uptake of LDL is 
mediated by increased LDLR expression by the activation of SREBP-2 driven 
by the low level of cellular cholesterol. However, the expression of PCSK9 
also increases as the expression of LDLR increases because PCSK9 is the 
target of SREBP-2, hindering the statins from decreasing the plasma 
cholesterol level. In case when PSCK9 was knocked-out, it was observed that 
the expression of LDLR increases in a greater amount by statin than that in 
wild-type, thus the blood cholesterol level drops more effectively.11 Therefore, 
it is expected that the use of PCSK9 inhibitors will augment the effect of 
statin, and the benefit of PCSK9 inhibitors is currently under extensive studies 
as a therapeutic modality of hypercholesterolemia treatment. 
Recently, the role of microRNA (miRNA) on gene expression is being 
widely studied, particularly in the field of cancer biology. miRNAs are small 
non-coding RNAs which consist of ~22 nucleotides, bind to the 3’-
untranslated region (UTR) of target mRNAs and regulate the post-
transcriptional expression of target genes.12 Up to now, about thousands of 
miRNA has been discovered and since one miRNA is able to target many 
different genes, it is thought about miRNA that over 30% of human genes can 
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be regulated by miRNA.13 Mainly, researches of miRNA have focused on 
cancer, specifically related to cell activities such as tumorigenesis, 
differentiation, metabolism, and apoptosis have been under progress. 
Researches on cell metabolism and miRNA have become more active 
recently and researchers like Rayner et al. have discovered that miR-33 
represses the expression of adenosine triphosphate-binding cassette (ABC) 
transporter, which has the role of secreting cellular cholesterol out of the cell 
in the form of apolipoprotein A1 (ApoA1).14 Also, it is already a widely 
known fact that miR-122 is involved in the metabolism of fatty acid and 
cholesterol.15 Moreover, it has been discovered that miRNA-370 is involved 
in the oxidation process of fatty acid through regulating miR-122 
expression.15 However, researches on miRNAs particularly targeting genes 
that role in the cellular lipid metabolism are still at an early stage, thus it is 
thought that more discoveries will be found in this field. 
The purpose of this research is to discover a new mechanism for 
regulating cellular cholesterol level mediated by miRNAs targeting PCSK9. 
Finding miRNAs that regulate the expression of PCSK9 will be a potential 
modality of hypercholesterolemia treatment. 
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II. MATERIALS AND METHODS 
 
1. General methods and supplies 
DNA manipulations were performed using standard molecular biology 
techniques. Delipidated serum (DLPS) was prepared from FBS as described 
by Hannah et al.16 Protein concentrations were determined using a BCA kit 
(Pierce, Rockford, IL USA). Cell culture medium and reagents were obtained 
from invitrogen (Calsbard, CA, USA). N-acetyl-leucine-leucine-norleucinal 
was obtained from Merck Biosciences (Calbiochem, San Diego, CA, USA). 
Rosuvastatin was kindly provided by AstraZeneca (Mölndal, Sweden). 
Sodium mevalonate was prepared from mevalonic acid lactone (Sigma-
Aldrich, Co. St. Louis, MO, USA) as follows.17 To prepare 1.0 M sodium 
mevalonate, 5 g of mevalonic acid lactone was dissolved in distilled water, 
then 4 ml of 10 N NaOH was added drop-wise and stirred for 40 min at room 
temperature. The pH of the solution was adjusted by 0.5 N HCL to pH 7.5, 
then the final volume was brought to 38.4 ml with distilled water. The stock 
solution was filter-sterilized, divided into aliquots, and stored at -20°C until 
use. mirVana™ negative control (miR-NC, Cat #4464059), mirVana™ 
miRNA mimics (miR-224, ID: MC12571; miR-1912, ID: MC14695) and 
mirVana™ miRNA inhibitors (miR-224, ID: MH12571; miR-1912, ID: 
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MH14695) were purchased from Ambion Inc. (Bedford, MA, USA). Dil-LDL 
was purchased from Biomedical Technologies Inc (Stoughton, MA, USA). 
Other reagents not specified were obtained from Sigma-Aldrich. The 
following antibodies were used in the current studies: anti-IDOL from Abcam 
(Cambridge, UK), and anti-GAPDH from Cell signaling Technology, Inc. 
(Beverly, MA, USA). Horseradish peroxidase-conjugated secondary 
antibodies were obtained from Pierce. The polyclonal antibodies against 
human PCSK9, SREBP-2 were prepared as previously described by Jeong et 
al.10 The polyclonal antibody against human LDLR was raised in rabbits using 
synthetic peptide spanning amino acids 832-841 of bovine LDLR according 
the standard technique. 
 
2. Cell culture and transfection 
HepG2 (American Type Culture Collection number HB-8065) cells were 
maintained in medium A (DMEM containing 100 U/ml penicillin and 100 
μg/ml streptomycin sulfate) supplemented with 10% (v/v) FBS. Transfection 
of miRNA mimics or miRNA inhibitors into HepG2 cells in suspension was 
carried out using Lipofectamine™2000 (Invitrogen) according to the method 
described by Notarangelo et al. with minor modifications.18 Briefly, miRNA 
mimics or miRNA inhibitors were complexed in Opti-MEM (Invitrogen) 
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using Lipofectamine™2000 according to the manufacturer's instruction. 
While the miRNA mimics or inhibitor-lipofectamine complex was prepared, 
HepG2 cells were trypsinized and suspended in medium A supplemented with 
10% FBS. The complex was mixed with 2 × 105 cells per well/12-well plate 
in 0.8 ml of medium A supplemented with 10% FBS and rocked gently for 20 
min at 37°C in the tube. Aliquots of mixtures were plated on 12-well plates 
and cultured overnight at 37°C under a humidified atmosphere of 5% CO2. 
For the treatment of cells with or without sterols, on day 1, cells were washed 
twice with PBS and changed to medium A supplemented with 10% DLPS, 0.1 
μM rosuvastatin, and 50 μM sodium mevalonate in the absence or presence of 
1 μg/ml 25-hydroxycholesterol plus 10 μg/ml cholesterol added in a final 
concentration of 0.2% (v/v) ethanol. On day 2, cells were washed twice with 
PBS, harvested for further analyses. Transfection of plasmids into HEK293 
cells was carried using Lipofectamine™2000 (Invitrogen) according to the 
manufacturer’s instruction. 
 
3. Quantification of miRNA and mRNA expression 
Total RNA including the miRNA fraction was isolated using miRNeasy 
micro kit (Qiagen, Hiden, Gemany) according to the manufacturer’s 
instruction. Removal of DNA from RNA was achieved with RNase-free 
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DNase (Qiagen). For mRNA quantification, cDNA was synthesized from 2 μg 
of DNase-treated RNA using a High capacity cDNA synthesis kit (Applied 
Biosystems, Foster sity, CA, USA). Quantitative real-time PCR (qRT-PCR) 
was performed using the PowerSYBR® Green PCR master (Applied 
Biosystems). For miRNA quantification, cDNA was synthesized from 10 ng 
of total RNA using specific miRNA primers supplied by the specific 
TaqMan® Micro Assay and TaqMan® MicroRNA reverse transcription kit 
(Applied Biosystems). TaqMan® Universal master mix and specific 
TaqMan® Micro Assay (Applied Biosystems) were used for qRT-PCR All 
reactions were analyzed using the StepOne™ Real-time PCR systems 
(Applied Biosystems). GAPDH and U6 snRNA were used as references for 
mRNA and miRNA, respectively. Each sample was analyzed in triplicate and 
the relative amounts were quantified by the comparative cycle-time method. 
The primers and TaqMan® Micro Assay used for qRT-PCR are shown in 
Tables 1 and 2. 
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Table 1. Primers used for quantitative real-time PCR 
 
Table 2. Taqman assays for quantitative real-time PCR 
miRbase ID miRBase Accession No. TaqMan Assay ID 
U6 snRNA NR_004394 001973 
hsa-miR-224 MIMAT0007887 002099 
has-miR-1912 MIMAT0000281 121110_mat 
Gene 
symbol  
NCBI Accession 
No.  Sequence (5ʹ to 3ʹ) 
GABRE NM_174936.3 
FW: GGCAGGTTGGCAGCTGTTT 
RV: CGTGTAGGCCCCGAGTGT 
GAPDH NM_001256799.2 
FW: TGTGTCCGTCG-TGGATCTGA 
RV: CCTGCTTCACCACCTTCTTGAT 
LDLR NM_000527.4 
FW: GGCTGCGTTAATGTGACACTCT 
RV: CTCTAGCCATGTTGCAGACTTTGT 
PCSK9 NM_174936.3 
FW: GGCAGGTTGGCAGCTGTTT 
RV: CGTGTAGGCCCCGAGTGT 
SREBF2 NM_004599.3 
FW: CGGTAATGATCACGCCAACAT 
RV: TGGTATATCAAAGGCTGCTGGAT 
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4. Immunoblot analysis 
After treatment of cells as described in each figure legend, cells were 
washed twice with PBS and lysed with 200 μl of NUN buffer containing 0.33 
M NaCl, 1.1 M urea, 1% Nonidet P-40, 25 mM HEPES (pH 7.6), and protein 
inhibitors (1 mM DTT, 10 μg/ml leupeptin, 1 mM PMST, 2 μg/ml aprotinin, 
and 50 μg/ml N-acetyl-leucine-leucine-norleucinal) by adding directly onto 
the plate.19 Cell lysates were harvested and further vortexed at room 
temperature for 10 min for the complete liberation of proteins. Lysates were 
cleared by centrifugation at 20,000 g for 15 min at 4°C, and the supernatants 
were collected as whole cell lysate. After quantitation of protein, aliquots of 
proteins were subjected to 8% SDS-PAGE and transferred onto nitrocellulose 
ECL membranes (GE healthcare, Piscataway, NJ, USA), and immunoblot 
analyses were performed using the Supersignal West Pico Chemiluminescent 
Substrate System (Pierce). 
 
5. Screening of miRNAs targeting PCSK9 
The 3ʹUTR sequence of the human PCSK9 mRNA was retrieved using 
Entrez (http://www.ncbi.nlm.nih.gov/entrez/). Then the sequence was 
analyzed to reveal binding sites for potential miRNAs targeting human 
PCSK9 by using on-line computational algorithm: miRanda 
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(http://www.microrna.org) and TargetScan (http://www.targetscan.org). Then, 
predicted miRNAs were listed according to the Context+ score or the mirSVR 
score by TargetScan or miRanda, respectively. 
 
6. The luciferase reporter assay 
The PCSK9 3ʹUTR luciferase reporter (pLightSwitch_PCSK9_3UTR) 
construct harboring the complete 3ʹUTR of the human PCSK9 mRNA at 
down-stream of renilla luciferase gene was purchased from Switchgear 
Genomics (Melno Park, CA, USA). Site-directed mutagenesis of the putative 
seed regions in the 3ʹUTR for miRNAs was performed using pfu DNA 
polymerase (Agilent technologies, Palo Alto, CA, USA) to create mutant 
variants of the PCSK9 3ʹUTR luciferase reporter construct. Primer sequences 
and genomic location used for mutagenesis are shown in Table 3. For 
luciferase reporter assays, HEK293 cells were plated in a 24-well plate and 
then cotransfected with 80 ng of firefly luciferase control vector (pGL3-
control, Promega, Madison, WI, USA), 200 ng of the 3ʹUTR luciferase 
reporter construct, and 40 nM (final concentration) of miRNA mimic using 
Lipofectamine™2000 (Invitrogen) according to the manufacture’s instruction. 
Cells were lysed 48 h after transfection and luciferase activity was measured 
by Dual Luciferase Reporter Assay System (Promega). The pGL3-Control 
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was cotransfected with the construct as an internal control to standardize 
transfection efficiency. The renilla luciferase activity representing the activity 
of the 3ʹUTR of PCSK9 mRNA was normalized to the firefly luciferase 
activity driven by pGL3-Control vector, and the amount of protein in the 
lysate. Transfection were done in duplicate and repeated at least thrice in 
independent experiments. The results were shown as the fold change between 
selected miRNA mimics and a negative control miRNA mimic for each 
3ʹUTR vector. 
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Table 3. Primers used for site directed mutagenesis of PCSK9 3ʹUTR 
luciferase reporter 
Plasmid  Sequence (5ʹ-3ʹ) 
Mut-1 FW ATTAATATGGTGACTGTTTAAAATAAAAACA 
Mut-2 FW ATTTTTATTAATATGTTGACGTTTTAAAATAA 
Mut-3 FW TTTTTATTAATATGGTGCCTTTTTAAAATAAAAAC 
Mut-4 FW GAAGATATTTATTCTTGTTTTTGTAGCATTTTT 
Mut-5 FW TTGAAGATATTTATTATGGGTTTTGTAGCAT 
Mut-6 FW CTTGAAGATATTTATAATGGGTTTTGTAGCATT 
(miRNA target sites are underlined and point mutations are indicated in 
italic.) 
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7. Fluorescence microscopy and LDL uptake assay 
Twenty four hr after transfection, cells were incubated with 10% DLPS 
culture medium for 24 h followed by treatment for 3 h with 2 μg/ml of 
fluorescence-labeled Dil-LDL. Cells were washed twice with PBS and 
fluorescence images were gained by using fluorescence microscope (Olympus, 
Tokyo, Japan) with rhodamine filter. For quantification of LDL uptake, cells 
were trypsinized to obtain a single-cell suspension. The mean fluorescence 
intensities of 10,000 cells were analyzed by fluorescence-activated cell sorting 
on the FACScan (BD Bioscience, San Jose, CA USA). 
 
8. Human liver samples 
Human liver specimens were obtained from Severance Hospital Gene 
Bank at Yonsei University College of Medicine (Seoul, Korea). This study 
was a retrograde study and all protocols were approved by the Institutional 
Review Board of Yonsei Health Systems (Seoul, Korea, IRB No. 4-2013-
0011). The histological classification of the specimen as a tumor or the 
matched adjacent normal tissue followed the data provided by the Severance 
Hospital Gene Bank. 
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9. Statistical analysis 
Three experiments were performed for all in vitro studies. The results are 
presented as means ± standard deviation (SD). The data were subjected to a 
two-tailed Student’s t-test. The Spearman’s rank-order correlation coefficient 
testing was used to evaluate the strength of a link between miRNA and protein 
levels. Statistical analyses were carried out using SPSS version 18.0 for 
Windows (Statistical Package for the Social Science, SPSS, Ins., Chicago, 
USA). All P values less than 0.05 were considered statistically significant. 
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III. RESULTS 
1. Bioinformatic analyses of potential miRNAs regulating PCSK9  
To search miRNA candidates targeting PCSK9, two algorithms including 
TargetScan and miRanda were used. Both algorithms predicted several 
miRNAs to be candidates targeting PCSK9. miRNAs with lower Context+ 
score in Targetscan or lower mirSVR score in miRanda might be more 
favorable candidates as regulator of target gene, they were listed in order of 
score (Table 4). Six miRNAs, miR-24, miR-99b, miR-149, miR-224, miR-601, 
and miR-1912, which were overlapped in top 10 ranked lists of both 
algorithms, were selected for further studies.  
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Table 4. Top 10 possible PCSK9 targeting miRNAs predicted by 
TargetScan and miRanda 
TargetScan miRanda 
miRNA Context+ score miRNA mirSVR score 
has-miR-99b -0.52 has-miR-29b -1.25 
has-miR-24 -0.52 has-miR-187* -1.23 
has-miR-191 -0.38 has-miR-1912 -1.11 
has-miR-1912 -0.34 has-miR-224 -1.09 
has-miR-1972 -0.3 has-miR-601 -1.05 
has-miR-601 -0.29 has-miR-616* -1.04 
has-miR-564 -0.29 has-miR-374b -0.80 
has-miR-224 -0.27 has-miR-24 -0.57 
has-miR-149 -0.24 has-miR-149 -0.44 
has-miR-571 -0.24 hsa-miR-99b -0.35 
(Overlapped miRNAs are indicated in bold.)  
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2. Screening of putative miRNAs regulating PCSK9 by immunoblot 
assay   
To determine whether selected miRNAs affect PCSK9 expression in vitro, 
amounts of PCSK9 and LDLR were evaluated after transient transfection of 
each miRNA in HepG2 cell (Fig. 1). Among predicted miRNAs, miR-1912 
reduced the amount of PCSK9 most effectively with marked increase in the 
amount of LDLR. miR-224 reduced the amount of PCSK9 slightly, however, 
the increase in the amount of LDLR was considerably high comparable to that 
increased by miR-1912. miR-149 reduced the amount of PCSK9, however, it 
showed no effect on LDLR. Effects of miR-24, miR-99b, and miR-601 on 
amounts of PCSK9 and LDLR were relatively small compared to that of miR-
224 and miR-1912. Accordingly, miR-224 and miR-1912 were selected for 
further evaluation for its potentials of regulating PCSK9 and cellular 
cholesterol metabolism via LDLR.  
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 Figure 1. Effects of miRNAs which were predicted to target PCSK9 by 
bioinformatic algorithms on the expression of LDLR and PCSK9  
On day 0, HepG2 cells were transfected with each miRNA mimic at a final 
concentration of 40 nM as described in Material and Methods. On day 1, cells 
were switched to fresh medium A supplemented with 10% delipidated serum 
(DLPS). On day 2, cells were switched to fresh medium A supplemented with 
10% DLPS and 0.1 μM of rosuvastatin and 0.05 mM of sodium mevalonate. 
On day 3, 16 h after incubation, cells were harvested and immunoblot analysis 
was carried out with polyclonal antibodies against PCSK9, and the low 
density lipoprotein receptor (LDLR). GAPDH was used as a loading control. 
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3. miR-224 and miR-1912 regulate amounts of PCSK9 and LDLR 
proteins 
The change of PCSK9 and LDLR expression was validated by qRT-PCR 
(Fig. 2A, B). The amount of PCSK9 mRNA was significantly decreased by 
miR-224 and miR-1912. miR-224 reduced the amount of LDLR mRNA, while 
miR-1912 did not. The reduction of LDLR mRNA could be caused either by 
direct action of miR-224 or secondarily by the change of cholesterol 
metabolism driven by miR-224-mediated changes in PCSK9 expression. 
Immunoblot analysis revealed that these miRNAs reduced PCSK9 protein 
level regardless of cholesterol treatment in the cells and effectively blocked 
rosuvastatin-induced up-regulation of PCSK9 (Fig. 2C). The amount of 
LDLR protein was increased accordingly. The amount of SREBP-2 mRNA 
was decreased by both miR-224 and miR-1912. However, the protein level of 
the nuclear form of SREBP-2, which activates PCSK9 transcription, was not 
affected by miRNAs.  
Effects of miR-1912 to reduce PCSK9 protein and to increase LDLR 
protein were revealed to be in a dose-dependent manner up to final 
concentration of 80 nM (Fig. 2E). MiR-224 caused the similar dose-dependent 
reduction of PCSK9 protein and increase in LDLR protein (Fig. 2D). On the 
contrary, when cells were cotransfected with miRNAs and antisense 
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oligonucleotides (anti-miR, miRNA inhibitors), which silence the action of 
miRNAs, the effects of miRNAs on PCSK9 and LDLR protein were 
attenuated significantly (Fig. 2F).  
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 Figure 2. Effects of miR-224 and miR-1912 on the expression of LDLR 
and PCSK9 in HepG2 cells 
(A, B) On day 0, HepG2 cells were transfected with miRNAs at a final 
concentration of 40 nM as described in Material and Methods. On day 1, cells 
were switched to fresh medium A supplemented with 10% DLPS. On day 2, 
cells were switched to fresh medium A supplemented with 10% DLPS, 0.1 
μM of rosuvastatin, and 0.05 mM of sodium mevalonate. On day 3, 16 h after 
incubation, total RNAs from cells were prepared and subjected to reverse 
transcription and qRT-PCR as described in Materials and Methods. Each value 
represents the amount of mRNA relative to that in the cells transfected with 
miR-NC, which was arbitrarily defined as 1. miR-NC or NC denotes the 
negative control miRNA mimic. The values represents the mean ± SD 
(*P<0.05). (C) After cells were transfected and incubated as described Fig.2A, 
on day 2, cells were switched with 10% DLPS or 0.1 mM rosuvastatin and 
0.05 mM sodium mevalonate, or 1 μg/ml 25-hydroxycholesterol and 10 μg/ml 
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cholesterol as indicated in the figure. After 16 h of incubation, on day 3, cells 
were harvested and immunoblot analysis was carried out as described for Fig. 
1. (D, E) On day 0, HepG2 cells were transfected with the indicated 
concentration of miR-224, or miR-1912 on 12-well plates as described above. 
The total amounts of transfected miRNA mimics were adjusted to 80 nM per 
well with a miR-NC. Cells were incubated and harvested, and immunoblot 
analysis was carried out as described for Fig. 1. (F) On day 0, HepG2 cells 
were transfected with the indicated miRNA mimics at final concentration of 
40 nM and the indicated antisense oligonucleotides against miRNAs (anti-
miR) at final concentration of 100 nM as described above. Cells were 
incubated and harvested, and immunoblot analysis was carried out as 
described for Fig. 1. 
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4. miRNAs targets the 3ʹUTR of PCSK9 mRNA 
 In order to verify whether miRNAs affect PCSK9 expression via the 
3ʹUTR of PCSK9 mRNA, the sequence used for predicting the miRNAs by 
TargetScan and miRanda analysis, luciferase reporter assay was carried out 
using pLightSwitch_PCSK9_3UTR which contains the entire 3ʹUTR of 
PCSK9 mRNA flanked to the downstream of renilla luciferase reporter gene 
(Fig. 3A). Sequences of putative binding sites for miR-224 and for miR-1912 
and for unrelated sites are depicted in Fig. 3B and Fig. 3D, respectively, and 
locations of introduced mutations are indicated. Co-transfection into HEK293 
cells with the wild-type construct with miR-224 or miR-1912 resulted in 
decreased luciferase activity as compared to luciferase activity in cells co-
transfected with the control miRNA mimic (WT in Fig. 3C, E). When 
mutations are introduced to putative binding regions for miRNAs in the 
3ʹUTR by site-directed mutagenesis (Mut-1, -2, and -3 in Fig. 3C and 3E), the 
luciferase activity remained unchanged by miRNAs. However, introduction of 
the mutation at the region unrelated to the predicted binding region in the 
3ʹUTR showed no effect on reduction of the wild-type reporter activity by 
miRNAs (Mut-4 in Fig. 3C and 3E). These results suggested that miR-224 
and miR-1912 reduce the expression of PCSK9 by targeting the 
corresponding regions in PCSK9 mRNA specifically.
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 Figure 3. Specific interaction between selected miRNAs and the 3ʹUTR of 
PCSK9 mRNA 
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(A) Schematic representation of the luciferase reporter vector harboring the 
PCSK9 3ʹUTR fragment (gray box). (B) Interaction between miR-224 and 
PCSK9 3ʹUTR predicted by TargetScan and miRanda. The interaction is 
highlighted in bold font. Point mutations were generated within the binding 
region by site-directed mutagenesis as described in Material and Methods, and 
are underlined. The name of each construct is shown at left. (C) Relative 
luciferase activities after co-transfection of PCSK9 3ʹUTR vectors with miR-
224. HEK293 cells were co-transfected with pGL3 control, indicated PCSK9 
3ʹUTR reporter, and indicated miRNA mimics as described in Material and 
Methods. After 48 h of incubation, cells were harvested and the luciferase 
activities were measured. The luciferase activities were normalized with 
firefly luciferase activities and the amounts of proteins used for assays. Each 
value represents the luciferase activities of indicated 3ʹUTR reporter 
constructs in the cells co-transfected with miR-224 relative to that in the cells 
co-transfected with miR-NC, which was arbitrarily defined as 1. Each value 
represents the mean ± SD (*P<0.05). (D) Interaction between miR-1912 and 
PCSK9 3ʹUTR predicted by TargetScan and miRanda. The interaction was 
highlighted in bold font and mutant vectors which have point mutations inside 
or outside the binding region are shown. (E) Relative luciferase activities after 
co-transfection of PCSK9 3ʹUTR vectors with miR-1912. The luciferase 
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activities of indicated 3ʹUTR reporter constructs in the cells co-transfected 
with miR-1912 were normalized to that in the cells co-transfected with miR-
NC. Each value represents the mean ± SD (*P<0.05). 
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5. miRNAs induce the uptake of LDL-cholesterol 
To investigate whether the change of PCSK9 expression by miRNAs 
affects cholesterol metabolism via LDLR, the effect of miRNAs on LDL-
cholesterol uptake was evaluated. After miRNAs were transfected, cells were 
incubated in a media containing fluorescent-tagged LDL (Dil-LDL). Then, 
fluorescence microscopy images were obtained and the uptake of Dil-LDL 
was measured through FACS analyses. Compared to the miR-NC transfected 
cells, the miR-224 transfected cells contained more red Dil-LDL particles (Fig. 
4A). When a histogram of fluorescence intensity was composed using FACS, 
the histogram of selected miRNAs transfected cells resulted in a shift-to-left, 
indicating a relative increase cellular LDL-cholesterol uptake (Fig. 4B). MiR-
224 increased fluorescence intensity by 20% and miR-1912 demonstrated a 
relative increase in Dil-LDL uptake by 70% or greater (Fig. 4C). 
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 Figure 4. Enhanced cellular uptake of LDL-cholesterol by selected 
miRNAs 
(A) Fluorescence microscopic images of Dil-LDL uptake in HepG2 cells 
33 
 
(x400). On day 0, HepG2 cells were transfected with miR-NC, miR-224 
mimic, and miR-1912 mimic at final concentration of 40 nM as described in 
Material and Methods. On day 1, cells were switched to fresh medium A 
supplemented with 10% DLPS. On day 2, cells were switched to fresh 
medium A supplemented with 10% DLPS again. After 16 h of incubation, on 
day 3, cells were switched to fresh medium A added with 2 μg/ml of Dil-LDL. 
After 3 h of incubation, cells were washed twice with PBS and fluorescence 
microscopic images were taken. (B, C) After microscopic image acquisition, 
cells were trypsinized, and suspended in PBS, and analyzed with the flow 
cytometer. Mean fluorescence intensities (MFI) of 104 cells were analyzed by 
histogram and quantified. Histograms represent distribution of fluorescence 
intensities of Dil-LDL in cells transfected with miRNA mimics (red line). 
Diagrams show MFI of Dil-LDL in cells transfected with miRNA mimics 
relative to that in cells transfected with miR-NC. Each value represents the 
mean ± SD (*P<0.05). 
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6. Evaluation of physiologic regulation of selected miRNAs by 
cholesterol status in HepG2 cells 
The expression of PCSK9 and LDLR is regulated by localization of 
SREBP-2 according to cellular cholesterol level. In order to evaluate whether 
these miRNAs have physiologic role to regulate cholesterol level, it was 
essential to validate the change of the endogenous expression of miRNAs 
targeting PCSK9 by cholesterol status. miR-224 resides in the intron 6 of 
gamma-aminobutyric acid (GABA) A receptor family epsilon subunit 
(GABRE) on the X chromosome (Fig. 5A). The putative miR-224 binding 
sites of PCSK9 3ʹUTR are highly conserved across species (Fig. 5B). In 
addition, the seed region of miR-224 are perfectly conserved (Fig. 5C).  
After treatment of rosuvastatin or cholesterol to HepG2 cell to change 
cellular cholesterol content, qRT-PCR was employed to examine the 
expression of miR-224 and its host gene, GABRE (Fig. 6A, B). The amount of 
miR-224 was increased by cholesterol depletion. However, extracellular 
cholesterol induced the expression of miR-224 as well. Furthermore, the 
expression of miR-224 was increased more in response to simultaneous 
treatment of rosuvastatin and cholesterol. The amount of GABRE mRNA was 
also increased by treatment of rosuvastatin or cholesterol, but its change 
pattern was not similar to that of miR-224 according to cellular cholesterol 
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level. 
Genomic locus of miR-1912 is in the intron 2 of the serotonin receptor 
2C (5-hydroxytryptamine receptor 2C; HTR2C) on the X chromosome (Fig. 
7A). The miR-1912 binding sites of PCSK9 3ʹUTR are conserved across only 
primates (Fig. 7B). Those of rodents are different in 2 nucleotides. The 
sequences, which are corresponsive to the seed region of human mature miR-
1912, are conserved across primate. However, mature forms of miR-1912 are 
different in length among species (Fig. 7C).  
The expression of miR-1912 and its host gene, HTR2C were examined 
by Taqman miRNA assay and qRT-PCR. They showed that Ct values were 
more than 35, suggesting miR-1912 and HTR2C did not express in HepG2 
cells.  
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 Figure 5. Genomic location of miR-224 and cross-species sequence 
conservation of miR-224 and its target site within the PCSK9 3ʹUTR 
(A) Schematic representation of the miR-224 coding sequence within 
GABRE. The sequences encoding the pre-miRNA are shown, with the mature 
miR-224 sequences highlighted in bold. (B) 3ʹUTR sequences of PCSK9 
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flanking miR-224 target sites are aligned among human, chimpanzee, rhesus, 
mouse, and rat. Conserved sequences are shown in bold. (C) The sequences of 
mature miR-224 are aligned across species. Conserved sequences in the seed 
region are shown in bold. GABRE, gamma-aminobutyric acid A receptor 
family epsilon subunit. 
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Figure 6. The expression of miR-224 and its host gene according to 
cellular cholesterol content 
(A, B) Expression of miR-224 and its host gene, GABRE in HepG2 cells 
after depletion or supplementation of sterols. On day 0, HepG2 cells were set 
up with medium A supplemented with 10% FBS. On day 1, the cells were 
switched to fresh medium A supplemented with 10% DLPS for 24 h. On day 2, 
cells were switched with 10% DLPS or 0.1 mM rosuvastatin and 0.05 mM 
sodium mevalonate, or 1 μg/ml 25-hydroxycholesterol and 10 μg/ml 
cholesterol as indicated in the figure. After 16 h of incubation, on day 3, total 
RNAs from the cells were prepared and subjected to reverse transcription and 
qRT-PCR as described in Material and Methods. Each value represents the 
amount of miRNA or mRNA relative to that in the cells grown in the absence 
of rosuvastatin, mevalonate, and sterols. All the values are expressed as the 
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mean ± SEM (*P<0.05). GABRE, gamma-aminobutyric acid A receptor 
family epsilon subunit. 
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 Figure 7. Genomic location of miR-1912 and cross-species sequence 
conservation of miR-1912 and its target site within the PCSK9 3ʹUTR 
(A) Schematic representation of the miR-1912 coding sequence within 
HTR2C. The sequences encoding the pre-miRNA are shown, with the mature 
miR-1912 sequences highlighted in bold. (B) 3ʹUTR sequences of PCSK9 
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flanking miR-1912 target sites are aligned among human, chimpanzee, rhesus, 
mouse, and rat. Conserved sequences are shown in bold. (C) The sequences of 
mature miR-1912 are aligned across species. Conserved sequences in the seed 
region are shown in bold. HTR2C, 5-hydroxytryptamine receptor 2C. 
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7. Endogenous miR-224 affects the expression of PCSK9 and the 
uptake of cholesterol 
Because miR-224 expressed in HepG2 cells, the effects of miR-224 
knockdown on PCSK9 expression were examined. After anti-miR-224 
transfection into HepG2 cells, the expression of mature miR-224 was 
examined by qRT-PCR. It showed that anti-miR-224 reduced endogenous 
miR-224 expression effectively (Fig. 8A) and increased PCSK9 mRNA level 
significantly (Fig. 8B). In addition, immunoblot analysis revealed that anti-
miR-224 increased the amount of PCSK9 and decreased the amount of LDLR 
(Fig. 8C). 
To evaluate the relationship between increasing PCSK9 expression and 
endogenous miR-224 levels, 3ʹUTR luciferase assay was carried out after 
transfection of anti-miR in HepG2 cells. In the contrast with the results of 
miR-224 mimic on PCSK9 3ʹUTR reporter assay (Fig. 3C), anti-miR-224 
increased the luciferase activity of PCSK9 3ʹUTR reporter in HepG2 cells. It 
suggests that the endogenous miR-224 regulates PCSK9 expression via 
specific miRNA-mRNA interaction. 
  
43 
 
 Figure 8. The effect of miR-224 inhibition on the expression of PCSK9 in 
HepG2 cells 
(A, B) On day 0, HepG2 cells were transfected with anti-miR negative 
control (anti-miR-NC), and anti-miR-224 at final concentration of 80 nM as 
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described in Material and Methods. On day 1, cells were switched to fresh 
medium supplemented with 10% DLPS. On day 2, cells were switched to 
fresh medium A supplemented with 10% DLPS. After 16 h of incubation, on 
day 3, total RNAs from the cells were prepared and subjected to reverse 
transcription and qRT-PCR as described in Materials and Methods. Each value 
represents the amount of mRNA relative to that in the cells transfected with 
anti-miR-NC, which was arbitrarily defined as 1. The values represents the 
mean ± SD (*P<0.05). (C) On day 3, cells were harvested and immunoblot 
analysis was carried out as described for Fig. 1. (D) 3ʹUTR reporter assay was 
performed in HepG2 cells as described for Fig. 3.  
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8. miR-224 could regulates another LDL receptor degradation 
mechanism 
TargetScan and miRanda also revealed that inducible degrader of the 
LDL receptor (IDOL), which induces the degradation of LDLR, could be 
another target of miR-224 (Fig. 9A). To evaluate the specific interaction 
between miR-224 and IDOL mRNA, which was predicted by bioinformatic 
algorithms, IDOL reporter assay was carried out. MiR-224 reduced the 
luciferase activity of WT reporter by 40%. However, the luciferase activities 
of reporters harboring mutated miR-224 binding site in IDOL 3ʹUTR were not 
changed by miR-224 (Fig. 9B). In order to evaluate endogenous miR-224 
effects on IDOL 3ʹUTR, reporter vectors were transfected in cells without 
miR mimics. Interestingly, the luciferase activity of mutant vector harboring 
totally mutated miR-224 binding region was increased significantly compared 
to that of WT vector (Fig. 9C). It showed that endogenous miR-224 could 
regulate the IDOL expression.   
For further evaluation of this possibility, IDOL protein expressions and 
miR-224 expressions were examined in human hepatocellular carcinoma 
sample as miR-224 is known to be increased in hepatocellular carcinoma.20,21 
In tumor tissues IDOL protein expressions were significantly decreased in 
immunoblotting analysis (Fig. 10A). Furthermore, qRT-PCR results showed 
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that miR-224 expression were up-regulated 17 folds on average in tumor 
tissues compared to those in paired normal tissues (Fig. 10B). IDOL protein 
levels were inversely correlated with miR-224 expression in human tissue 
samples (r=-0.596, p=0.015) (Fig. 10C). 
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 Figure 9. Specific interaction between miR-224 and 3ʹUTR of IDOL 
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(A) Interaction between miR-224 and IDOL 3ʹUTR predicted by TargetScan 
and miRanda. The interaction is highlighted in bold font. Point mutations 
within the binding region were generated by site-directed mutagenesis as 
described in Material and Methods, and are underlined. (B) 3ʹUTR reporter 
assays using WT or mutated vectors were performed as described for Fig. 3. 
(C) The luciferase activities of IDOL 3ʹUTR WT reporter vector and IDOL 
3ʹUTR mut-3 reporter vector were compared in HepG2 cells. HEK293 cells 
were co-transfected with pGL3 control, and indicated IDOL 3ʹUTR reporter 
as described in Material and Methods. After 48 h of incubation, the luciferase 
activities were measured and are represented relative to that in the cells 
transfected with WT reporter. Each value represents the mean ± SD (*P<0.05). 
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Figure 10. The expression levels of miR-224 and IDOL in clinical 
specimens 
(A) Protein expressions were examined by immunoblotting 15 pairs (N, 
normal; T, tumor) of liver samples. (B) miR-224 expression levels were 
quantified by qRT-PCR and those of tumor tissues normalized to those of 
normal tissues on average. (C) Protein levels were quantified with imageJ 
software. IDOL protein levels in tumor tissues were normalized to those in 
paired normal tissues. Correlation analysis of miR-224 expression and IDOL 
protein levels in tumors was performed (r=-0.596, P=0.015).
51 
 
IV. DISCUSSION 
Cholesterol is essential for most vertebrates as an important component 
in cellular membrane and a precursor in metabolic pathways, but excess of 
cholesterol can cause atherosclerosis and cardiovascular disease.22 Therefore 
cholesterol homeostasis has to be strictly regulated in the body. Classical 
concept of regulating cholesterol metabolism is a coordination of 2 
transcription factor, liver receptor X (LXR) and SREBP-2.8,23,24 When excess 
cholesterol is accumulated in cells, LXR activates the expression of genes 
involved cholesterol efflux. By contrast, SREBP-2 induces cholesterol 
synthesis and uptake related genes.  
A class of non-coding RNAs termed miRNAs has emerged as important 
modulators of numerous cellular processes that affect organism’s growth, 
developments, homeostasis and disease.25 Recently the role of miRNA in 
metabolic homeostasis has been studied. Several studies revealed that miRNA 
is a potent posttranscriptional regulator of cholesterol metabolism in addition 
to the classic transcriptional regulation.26 
The purpose of this study was to discover miRNAs regulating PCSK9 
and to investigate whether these miRNAs affect cellular cholesterol 
homeostasis or not. The miRBase database provides all miRNA sequences 
and information about novel miRNAs using small RNA deep sequencing data 
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sets.27 In addition, multiple bioinformatic algorithms are available on the 
internet for identification of miRNAs targeting specific genes.28,29 They have 
been the most useful tools in predicting miRNA targets. However, each 
algorithm often shows different prediction results of miRNA candidates for 
one gene. It is reason that each algorithm may predict distinct miRNA binding 
sites and they analyze probabilities of miRNA-mRNA interactions differently. 
Therefore, it is recommended that at least two algorithms should be for more 
predictive accuracy.30    
In this study, 2 algorithms, TargetScan and miRanda, were used for 
prediction of miRNAs targeting PCSK9. Expectedly, both algorithms showed 
hundreds of miRNAs and their lists were different from each other in some 
degree. According to the probability score of functional miRNA-mRNA 
interactions, top 10 ranked miRNAs of both algorithms were compared and 
overlapped miRNAs were selected as potential regulators of PCSK9 for 
additional validation experiments. 
Specificity of miRNA target selection is affected by various unknown 
factors besides seed paring.31 Therefore experimental validation should be 
needed to confirm whether the predicted miRNAs are functional on certain 
biological process. For example, miR-99b, a top-ranked miRNA targeting 
PCSK9 in TargetScan, did not change the expression of PCSK9 (Fig. 1). 
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Hence among selected miRNAs, miR-224 and miR-1912 were finally selected 
through immunoblot results. 
miR-224 and its predicted binding sites on PCSK9 3ʹUTR are well 
conserved among vertebrae (Fig. 5). Well conserved miRNAs are thought to 
be vital and evolutionary ancient component of genetic regulation.32,33 For 
example miR-33 and its putative binding site in ABCA1 are well conserved 
across the species. MiR-33 locates within intron 16 of human SREBP-2.34 It 
has reported that SREBP2 and miR-33 are coexpressed and regulated by the 
change of cholesterol level.17 When intracellular cholesterol is depleted, the 
expression of SREBP2 is induced and the genes for cholesterol uptake or 
synthesis are activated by SREBP2. Simultaneously, increased miR-33 
represses ABCA1, which transports sterols from cells and mediates high-
density lipoprotein assembly, and functions in concert with its host gene to 
regulate cholesterol homeostasis.14,17,34,35 
Therefore miR-224 was supposed to play an evolutionary important role 
in cholesterol metabolism. However, it was disconcerting result that miR-224 
expression changed regardless of variation in cellular cholesterol (Fig. 6A). In 
this regards, the expression change of GABRE by cholesterol levels was 
evaluated but it was irrelevant to cellular cholesterol as well (Fig. 6B). These 
results were insufficient to support the role of miR-224 in cholesterol 
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metabolism regulation. Though, perhaps it is because most experiments were 
performed in HepG2 cell which miR-224 is pathologically increased.36 
Therefore, the more physiological condition should be needed to prove the 
role of miRNA in metabolic regulation. 
In comparison with conserved miRNAs, poorly conserved miRNAs are 
thought to be less important in regulation pathway. While, the different 
number of miRNAs and diversity of miRNAs among species seem to be a 
vital evolutionary mechanism of phenotypic diversification and speciation.37 
miR-1912 locates on intron 2 of HTR2C that expresses exclusively in 
neuronal cells.38 It is a quite impressive result which miR-1912 had great 
effect on cholesterol metabolism with significant decreasing PCSK9 and 
increasing LDLR. However, the function of endogenous miR-1912 on 
cholesterol metabolism could not be examined in this study because miR-
1912 does not express in HepG2 cells. To this day, the expression of miR-
1912 has been confirmed in just brain cortex and primary lymphocytes.39 At 
first PCSK9 was identified as a molecule involving neuronal differentiation.40 
Therefore it is conceivable that miR-1912 can be related with tissue specific 
or species specific regulation of cholesterol metabolism.   
It is known that single miRNA can target many genes.12,25 Besides 
PCSK9, other genes which involve the regulation of the LDL receptor had 
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been searched for their possibilities as target of miR-224. Bioinformatic 
algorithms predicted that miR-224 also targets IDOL which induces the 
degradation of LDLR as it name indicates. From IDOL 3ʹUTR reporter assay, 
the specific interaction between miR-224 and IDOL mRNA was proved. 
Furthermore, it was confirmed that the expression of miR-224 was inversely 
correlated with IDOL protein level in human hepatocellular carcinoma tissues 
(Fig. 10). The plasma cholesterol levels are lower in patients with 
hepatocellular carcinoma than in healthy subjects, because hepatic cellular 
damage impairs the process of cholesterol synthesis or absorption, leading to 
change in plasma lipid pattern.41 Recently several studies depict increase of 
miR-224 in hepatocellular carcinoma. miR-224 was found to influence 
migration and invasion of cancer cells during carcinogenesis.21,42,43 This study 
identified that miR-224 regulates cellular cholesterol uptake partially by 
controlling the IDOL expression which regulate the degradation of LDLR. 
This supports that the hypocholesterolemic trait is common in hepatocellular 
carcinoma patients, and provides some insights in the role of miRNA on 
cholesterol metabolism in cancer biology. 
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V. CONCLUSION 
When the predicted miRNAs was overexpressed, PCSK9 protein levels 
declined so that cellular cholesterol uptake rose. LDLR is in charge of 
cholesterol uptake and its degradation is regulated by PCSK9 and IDOL.44,45 
Up to this day, it is known that PCSK9 expression is controlled by 
transcription factors such as SREBP-2 or HNF-1.46 The present study showed 
that miRNAs directly controls PCSK9 protein levels with specific miRNA-
mRNA interactions. Especially the change of endogenous miR-224 levels 
affects PCSK9 proteins levels, as a result the amount of LDLR protein alters 
significantly. It would expand our knowledge of how PCSK9 is regulated 
besides transcriptional regulation mechanisms. Also miR-1912 showed 
noteworthy suppression of PCSK9 so it would be helpful to research the new 
PCSK9 inhibitors even though off-target effects of miR-1912 should be 
investigated. 
57 
 
REFERENCES 
1. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. 
Receptor-mediated endocytosis: concepts emerging from the LDL 
receptor system. Annu Rev Cell Biol 1985;1:1-39. 
2. Gent J, Braakman I. Low-density lipoprotein receptor structure and 
folding. Cell Mol Life Sci 2004;61:2461-70. 
3. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, 
et al. Binding of proprotein convertase subtilisin/kexin type 9 to 
epidermal growth factor-like repeat A of low density lipoprotein 
receptor decreases receptor recycling and increases degradation. J 
Biol Chem 2007;282:18602-12. 
4. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, 
et al. Mutations in PCSK9 cause autosomal dominant 
hypercholesterolemia. Nat Genet 2003;34:154-6. 
5. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence 
variations in PCSK9, low LDL, and protection against coronary heart 
disease. N Engl J Med 2006;354:1264-72. 
6. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb 
Vasc Biol 2009;29:431-8. 
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. 
58 
 
Nature 1990;343:425-30. 
8. Brown MS, Goldstein JL. The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound 
transcription factor. Cell 1997;89:331-40. 
9. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown 
MS, et al. Combined analysis of oligonucleotide microarray data from 
transgenic and knockout mice identifies direct SREBP target genes. 
Proc Natl Acad Sci U S A 2003;100:12027-32. 
10. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-
dependent regulation of proprotein convertase subtilisin/kexin type 9 
expression by sterol-regulatory element binding protein-2. J Lipid Res 
2008;49:399-409. 
11. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, 
et al. Decreased plasma cholesterol and hypersensitivity to statins in 
mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005;102:5374-9. 
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell 2004;116:281-97. 
13. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? 
Nat Rev Genet 2008;9:102-14. 
59 
 
14. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, 
Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol 
homeostasis. Science 2010;328:1570-3. 
15. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. 
MicroRNA-370 controls the expression of microRNA-122 and 
Cpt1alpha and affects lipid metabolism. J Lipid Res 2010;51:1513-23. 
16. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated 
fatty acids down-regulate srebp isoforms 1a and 1c by two 
mechanisms in HEK-293 cells. J Biol Chem 2001;276:4365-72. 
17. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 
induction to repression of sterol transporters. Proc Natl Acad Sci U S 
A 2010;107:12228-32. 
18. Notarangelo A, Latino R, Gasparini P, Zelante L, Fazio VM, Rinaldi 
M. Efficient transfection of adherent cells using cell suspensions. 
Focus 1997;19:58-9. 
19. Lavery DJ, Schibler U. Circadian transcription of the cholesterol 7 
alpha hydroxylase gene may involve the liver-enriched bZIP protein 
DBP. Genes Dev 1993;7:1871-84. 
20. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, et al. Profiling 
microRNA expression in hepatocellular carcinoma reveals 
60 
 
microRNA-224 up-regulation and apoptosis inhibitor-5 as a 
microRNA-224-specific target. J Biol Chem 2008;283:13205-15. 
21. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, 
Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is 
associated with clinical features and oncogene/tumor suppressor gene 
mutations. Hepatology 2008;47:1955-63. 
22. Tabas I. Cholesterol in health and disease. J Clin Invest 
2002;110:583-90. 
23. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the 
complete program of cholesterol and fatty acid synthesis in the liver. J 
Clin Invest 2002;109:1125-31. 
24. Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of 
oxysterol receptors. Curr Opin Genet Dev 1998;8:571-5. 
25. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 
2007;23:175-205. 
26. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic 
disorders. Nat Rev Mol Cell Biol 2012;13:239-50. 
27. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence 
microRNAs using deep sequencing data. Nucleic Acids Res 
2014;42:D68-73. 
61 
 
28. Rajewsky N. microRNA target predictions in animals. Nat Genet 
2006;38 Suppl:S8-13. 
29. Doran J, Strauss WM. Bio-informatic trends for the determination of 
miRNA-target interactions in mammals. DNA Cell Biol 2007;26:353-
60. 
30. Kuhn DE, Martin MM, Feldman DS, Terry AV, Jr., Nuovo GJ, Elton 
TS. Experimental validation of miRNA targets. Methods 2008;44:47-
54. 
31. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable 
predictor for miRNA-target interactions. Nat Struct Mol Biol 
2006;13:849-51. 
32. Chen K, Rajewsky N. The evolution of gene regulation by 
transcription factors and microRNAs. Nat Rev Genet 2007;8:93-103. 
33. Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J 
Mol Biol 2004;339:327-35. 
34. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten 
RE, et al. MicroRNA-33 and the SREBP host genes cooperate to 
control cholesterol homeostasis. Science 2010;328:1566-9. 
35. Bommer GT, MacDougald OA. Regulation of lipid homeostasis by 
the bifunctional SREBF2-miR33a locus. Cell Metab 2011;13:241-7. 
62 
 
36. Li Q, Wang G, Shan JL, Yang ZX, Wang HZ, Feng J, et al. 
MicroRNA-224 is upregulated in HepG2 cells and involved in 
cellular migration and invasion. J Gastroenterol Hepatol 2010;25:164-
71. 
37. Berezikov E. Evolution of microRNA diversity and regulation in 
animals. Nat Rev Genet 2011;12:846-60. 
38. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I. 
Distribution and cellular localization of the serotonin type 2C receptor 
messenger RNA in human brain. Neuroscience 1999;92:601-11. 
39. Zhang Z, Falaleeva M, Agranat-Tamir L, Pages A, Eyras E, Sperling J, 
et al. The 5' untranslated region of the serotonin receptor 2C pre-
mRNA generates miRNAs and is expressed in non-neuronal cells. 
Exp Brain Res 2013;230:387-94. 
40. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, 
Stifani S, et al. The secretory proprotein convertase neural apoptosis-
regulated convertase 1 (NARC-1): liver regeneration and neuronal 
differentiation. Proc Natl Acad Sci U S A 2003;100:928-33. 
41. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and 
lipoprotein metabolism. Lipids Health Dis 2006;5:4. 
42. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, et al. 
63 
 
MicroRNA-224 is up-regulated in hepatocellular carcinoma through 
epigenetic mechanisms. FASEB J 2012;26:3032-41. 
43. Yu L, Zhang J, Guo X, Li Z, Zhang P. MicroRNA-224 upregulation 
and AKT activation synergistically predict poor prognosis in patients 
with hepatocellular carcinoma. Cancer Epidemiol 2014;38:408-13. 
44. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low 
density lipoprotein receptor protein by proprotein convertase 
subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004;279:50630-
8. 
45. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates 
cholesterol uptake through Idol-dependent ubiquitination of the LDL 
receptor. Science 2009;325:100-4. 
46. Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, et al. Strong 
induction of PCSK9 gene expression through HNF1alpha and 
SREBP2: mechanism for the resistance to LDL-cholesterol lowering 
effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51:1486-
95. 
64 
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마이크로RNA에 의한  
PCSK9 및 콜레스테롤 항상성 조절 
 
<지도교수 박 상 욱> 
 
연세대학교 대학원 의과학과 
 
이 찬 주 
 
세포 표면의 저밀도 지단백 수용체는 혈중 저밀도 지단백 콜레스
테롤 세포 내로 흡수하는 역할을 하며 혈중 농도를 조절하는데 중
요하다. Proprotein convertase subtilisin/kexin type 9 (PCSK9)은 저밀도 지
단백 수용체와 결합을 해 세포 내부로 이동을 시켜 제거하며 이를 
통해 콜레스테롤 항상성을 조절한다. PCSK9의 전사는 스테롤 반응
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요소 결합 단백질 2에 의해서 조절이 된다고 알려져 있으나 아직까
지 마이크로RNA에 의한 조절기전은 밝혀진 바가 없다. 이 연구의 
목적은 PCSK9을 조절하고 콜레스테롤 항상성에 영향을 끼치는 마
이크로RNA의 존재를 밝히는 것이다. 마이크로RNA에 의한 PCSK9
의 전사 후 조절기전을 밝히기 위해서 바이오인포매틱 알고리즘을 
이용해서 PCSK9을 조절할 것으로 예측되는 마이크로RNA들을 스크
리닝하였다. 예측된 마이크로RNA 중에서 miR-224와 miR-1912가 웨
스턴 블롯 분석에서 PCSK9을 줄이고 저밀도 지단백을 증가시키는 
것을 확인하였다. 3ʹ untranslated region (3ʹUTR) luciferase assay는 이 마
이크로RNA들이 PCSK9 mRNA의 3ʹUTR 에 특이적으로 작용한다는 
것을 보여주었다. 형광 표식 저밀도 지단백 흡수 분석을 통하여 
miR-224나 miR-1912가 세포의 저밀도 지단백 흡수를 70%까지 증가
시키는 것을 확인하였다. 그리고 miR-224는 저밀도 지단백 수용체의 
유도를 일으키는 또 다른 물질인 inducible degrader of the LDL receptor 
(IDOL)을 조절하는 것을 3ʹUTR luciferase assay를 통해 확인하였다. 
이런 결과들은 마이크로RNA가 PCSK9이나 IDOL의 전사 후 조절을 
통해 콜레스테롤 항상성을 조절하는 또 다른 기전일 가능성을 의미
하며, 이런 점은 고지혈증 치료에 한가지 방법으로 응용할 가능성이 
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있음을 시사한다. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
핵심되는 말: PCSK9, 저밀도 지단백 수용체, 마이크로RNA, 
고콜레스테롤 
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